Perceptive Life Sciences, a fund that has outperformed the market, sold all of its 1 million shares of Novavax in the first few months of 2021 and bought millions more shares of three biopharma/biotech stocks in the same period.
The small-cap biopharmaceutical stock featured in today’s article is a Buy according to the consensus among analysts, who see upside potential of nearly 200% from current levels.
The company featured in today’s article finds itself at the intersection of biotech and cannabis – an intersection that could be worth $50 billion by 2029.
New Biotech World Order – surging share prices and booming initial public offerings of biotech stocks.
The two biotechs that are the focus of today’s article have been hot this year, with shares of both having experienced triple-digit growth. The reason? Their respective COVID-19 vaccine development programs, which have moved at lightning-fast speed.